Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2007 Jan 29;96(2):189-95. Epub 2007 Jan 9.

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Author information

1
Imaging Science and Biomedical Engineering, University of Manchester, Oxford Road, Manchester M13 9PT, UK.james.o'connor@manchester.ac.uk

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.

PMID:
17211479
PMCID:
PMC2359994
DOI:
10.1038/sj.bjc.6603515
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center